Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 287 clinical trials
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

) with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.

atopy
lebrikizumab
topical agents
eczema
  • 17 views
  • 07 Mar, 2021
  • 96 locations
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

received 2 or more lines of systemic therapy, including an anti-CD20 and anthracycline based chemotherapy and having failed to or are not candidates for ASCT. The study will consist of 2 parts: dose timing

b-cell lymphoma
anthracyclines
measurable disease
  • 17 views
  • 25 Jan, 2021
  • 8 locations
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

systemic therapy for metastatic disease.

advanced urothelial carcinoma
hearing loss
renal function
cancer
growth factor
  • 95 views
  • 05 Mar, 2021
  • 194 locations
Derazantinib in Subjects With FGFR2 Gene Fusion- Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

testing performed or commissioned by the respective study center) and who received at least one prior regimen of systemic therapy. Subjects will be dosed orally once per day at 300 mg of derazantinib

progestin
cholangiocarcinoma
cancer
anticoagulants
liver metastases
  • 190 views
  • 04 Feb, 2021
  • 51 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival

ulixertinib
cns tumors
beta-human chorionic gonadotropin
interferon
cns involvement
  • 990 views
  • 07 Mar, 2021
  • 113 locations
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

parallel cohorts based upon disease status or type and the planned systemic therapy following baseline tumor biopsy: (A) Androgen signaling inhibition, (B) Immunotherapy, (C) Radiotherapy, (D) Targeted

prostate carcinoma
serum testosterone
immunological adjuvant
prostate cancer metastatic
luteinizing hormone
  • 7 views
  • 28 Jan, 2021
  • 1 location
Synergism of Immunomodulation and Tumor Ablation

completion of 4-6 months first line systemic therapy. The primary objective of the study is to show an overall response rate of lesions not treated by ablation/radiotherapy including the extrahepatic

liver metastasis
gilbert's syndrome
cancer
stereotactic body radiation therapy
combination therapy
  • 41 views
  • 26 Jan, 2021
  • 14 locations
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

infections; assessment of relative treatment effect on secondary efficacy endpoints (clinical progression, time to next line of systemic therapy, time on therapy, overall and cancer specific

luteinizing hormone-releasing hormone agonist
degarelix
immunological adjuvant
androgen suppression
gonadorelin
  • 135 views
  • 23 Jan, 2021
  • 42 locations
PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer

will intensify radiotherapy or surgery unless widely metastatic disease is found, in which case systemic therapy will be intensified.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-na ve Non-small Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study

) in treatment-nave adults with no prior systemic therapy for their metastatic non-small cell lung cancer (NSCLC) whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS

  • 0 views
  • 11 Feb, 2021
  • 17 locations